Answers are grounded in this paper and cite their sources.
The live attenuated influenza virus vaccine (LAIV) is preferentially recommended for use in persons 2 through 49 years of age but has not been approved for children under 2 or asthmatics due to safety concerns. Therefore, increasing safety is desirable. Here we describe a murine LAIV with reduced pathogenicity that retains lethality at high doses and further demonstrate that we can enhance safety in vivo through mutations within NS1. This model may permit preliminary safety analysis of improved LAIVs.
No takes yet. Share an insight, caveat, or question.
Cox et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: